NCT03352674View on ClinicalTrials.gov

Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2018

Conditions
Diabetes Mellitus
Interventions
DRUG

Insulin Glargine Ezelin

Insulin Glargine (Ezelin) once daily at individually adjusted dose

DRUG

Insulin Glargine Pen Injector [Lantus]

Insulin Glargine (Lantus) once daily at individually adjusted dose

Trial Locations (1)

10520

Department of Internal Medicine Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia, Jakarta Pusat

All Listed Sponsors
lead

Indonesia University

OTHER

NCT03352674 - Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter